TrialInvestigational new drugs2019

E6201, an intravenous MEK1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastases.

Hani M Babiker et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.